Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 pharmacokinetics study of 14C-vosaroxin in advanced solid tumors
NL-OMON42076Phase 1Recruiting
- Sponsor
- Sunesis Pharmaceuticals, Inc.
- Start
- Nov 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vosaroxin in Nonhematologic neoplasms, sponsored by Sunesis Pharmaceuticals, Inc. Primary endpoint: Pharmacokinetics of 14C-vosaroxin and metabolites. Started Nov 2014; status: recruiting.
02
Drugs
vosaroxin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON42076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42076.